Oyster Point investors bet $93M on a PhIII study aimed at disrupting a major consumer market and toppling Allergan
Everyone who ever felt the tears well up in their eyes as they bit into a red hot chili pepper should be able to quickly gain a basic understanding of what Oyster Point Pharma is trying to do. The team there believes they’re on to a new and better way to treat dry eye disease. And they now have a whopping $93 million round from some sophisticated investors willing to back a Phase III to give it a final push — hopefully toward regulators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
